Pegbelfermin treatment for 12 weeks improved dyslipidemia and insulin sensitivity, increased adiponectin levels, and decreased ALT, AST, and Pro-C3 levels in obese patients with T2D (126). This evidence concerns the gene INS and metabolic syndrome.